<DOC>
	<DOC>NCT02396498</DOC>
	<brief_summary>The study is designed to assess the safety and efficacy of S-1 plus cisplatin hyperthermic intraperitoneal chemotherapy in stage Ⅲ patients after D2 gastrectomy</brief_summary>
	<brief_title>SP Intravenous Chemotherapy Versus SP by HIPEC in Stage Ⅲ Patients After D2 Gastrectomy</brief_title>
	<detailed_description>The study is a randomized clinical trial，and subjects wuill be assigned two arms: SP Intravenous Chemotherapy or SP by HIPEC .After 8 cycles treatment,we assess the safety and efficacy.</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>18 ≤ age ≤ 70 years old Histologically diagnosed as stageⅢ gastric adenocarcinoma，and perform D2 radical gastrectomy，as well as have not received any Antitumor therapy：chemotherapy,biological treatment or molecular targeted therapy , etc. The Eastern Cooperative Oncology Group (ECOG) status ≤ 2 Having given written informed consent prior to any procedure related to the study Expected survival time ≥3 months History of severe hypersensitivity reactions to the ingredients of S1 or Cisplatin Hemoglobin＜90g/L Inadequate hematopoietic function which is defined as below: white blood cell (WBC) less than 3,500/mm^3 absolute neutrophil count (ANC) less than 1,500/mm^3 platelets less than 80,000/mm^3 Inadequate hepatic or renal function which is defined as below: serum bilirubin greater than 2 times the upper limit of normal range alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2.5 times the ULN if no demonstrable liver metastases or greater than 5 times the ULN in the presence of liver metastases blood creatinine level greater than 1.5 times ULN,Creatinine clearance&lt;60ml/min Receiving a concomitant treatment with other fluoropyrimidine drug or flucytosine drug Women who is pregnant or lactating or fertile women of childbearing potential unless using a reliable and appropriate contraceptive method throughout the treatment period (Including male) Psychiatric disorder or symptom that makes participation of the patient difficult Myocardial infarction, existing serious or unstable angina, and patients with cardiac insufficiency in 6 months Severe complication(s), e.g., paresis of intestines, ileus, radiographically confirmed interstitial pneumonitis or pulmonary fibrosis, glomerulonephritis ,renal failure, poorlycontrolled diabetes Known DPD deficiency Participate in other clinical trial before the start of this trial Patient compliance is bad or researchers believe that patients are not suitable for this treatment Known to have active hepatitis patients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>